Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis;Taux de réponse à la clozapine chez des personnes souffrant de schizophrénie réfractaire au traitement: données d’une revue systématique et d’une méta-analyse

Canadian Journal of Psychiatry

Volumn 62, Issue 11, 2017, Pages 772-777

  Siskind, Dan ^a,b   Siskind, Victor ^c   Kisely, Steve ^a,b  

^a Metro South Addiction and Mental Health Service   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

clozapine; PANSS; response; schizophrenia; treatment resistant

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT-RESISTANT SCHIZOPHRENIA; OUTCOME ASSESSMENT; SCHIZOPHRENIA; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SCHIZOPHRENIA;

EID: 85034455415     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743717718167     Document Type: Article

References (33)

1. Howes OD, McCutcheon R, Agid O. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229.
2. Agid O, Arenovich T, Sajeev G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72(11):1439–1444.
3. Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997;14(1):1–20.
4. Siskind D, McCartney L, Goldschlager R. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–392.
5. Leucht S, Rothe P, Davis JM. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol. 2013;23(8):956–959.
6. Anscombe FJ. The transformation of Poisson, binomial and negative-binomial data. Biometrika. 1948;35(3/4):246–254.
7. Hartung J, Knapp G, Sinha BK. Statistical meta-analysis with applications. Hoboken (NJ): John Wiley; 2008.
8. Hong CJ, Chen JY, Chiu HJ. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol. 1997;12(3):123–130.
9. Wahlbeck K, Cheine M, Tuisku K. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24(6):911–922.
10. Benaroya H, Han SM. Probability models in engineering and science. Boca Raton (FL): Taylor & Francis; 2005.
11. Kane J, Honigfeld G, Singer J. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796.
12. Azorin JM, Spiegel R, Remington G. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158(8):1305–1313.
13. Bondolfi G, Dufour H, Patris M. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998;155(4):499–504.
14. Kumra S, Kranzler H, Gerbino-Rosen G. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5):524–529.
15. Kane JM, Marder SR, Schooler NR. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58(10):965–972.
16. Rosenheck R, Cramer J, Xu W. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337(12):809–815.
17. Bitter I, Dossenbach MR, Brook S. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):173–180.
18. Sacchetti E, Galluzzo A, Valsecchi P. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;110(1-3):80–89.
19. Tollefson GD, Birkett MA, Kiesler GM. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52–63.
20. Buchanan RW, Breier A, Kirkpatrick B. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998(6):751–760.
21. Cao HJ, You HF, Fan FL. The control study of risperidone and clozapine for the treatment-resistant schizophrenia. J Chin Med Res. 2003(4):316–319.
22. Kumra S, Frazier JA, Jacobsen LK. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53(12):1090–1097.
23. McEvoy JP, Lieberman JA, Stroup TS. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610.
24. Meltzer HY, Bobo WV, Roy A. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69(2):274–285.
25. Moresco RM, Cavallaro R, Messa C. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004;18(3):355–365.
26. Naber D, Riedel M, Klimke A. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005;111(2):106–115.
27. Shaw P, Sporn A, Gogtay N. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63(7):721–730.
28. Volavka J, Czobor P, Sheitman B. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255–262.
29. Wang R, Geng Y, Pan D. A comparative trial of efficacy of risperidone vs clozapine in treatment of refractory schizophrenia. Chin J Pharmacoepidemiol. 2002(5):230–231.
30. Hermes ED, Sokoloff D, Stroup TS. Minimum clinically important difference in the positive and negative syndrome scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry. 2012;73(4):526–532.
31. Bogers JP, Schulte PF, Van Dijk D. Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved? J Clin Psychopharmacol. 2016;36(2):109–111.
32. Forrester T, Siskind D, Winckel K. Increasing clozapine dispensing trends in Queensland, Australia 2004-2013. Pharmacopsychiatry. 2015;48(4/5):164–169.
33. Fibiger HC. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophr Bull. 2012;38(4):649–650.